Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jessica M. Clement is active.

Publication


Featured researches published by Jessica M. Clement.


BJUI | 2010

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

Toni K. Choueiri; Mei Sheng Duh; Jessica M. Clement; A. J. Brick; Miranda Rogers; Christabel Kwabi; Karishma Shah; Andrew Percy; Lucia Antras; Sujata S. Jayawant; Kristina Chen; Si-Tien Wang; Andi Luka; Maureen P. Neary; David F. McDermott; William Oh

Study Type – Symptom prevalence (case series)
Level of Evidence 4


Clinical Genitourinary Cancer | 2009

The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.

Jessica M. Clement; David F. McDermott

For patients with metastatic renal cell carcinoma (RCC), the prognosis is poor. Despite the recent approval of drugs such as sorafenib, sunitinib, and temsirolimus, durable remissions of metastatic disease are rare. This is largely due to the fact that these drugs, while effective, do not result in the eradication of disease. In 1992, the FDA approved the use of high-dose interleukin-2 (IL-2) for the treatment of patients with metastatic RCC because of a small number of patients that achieved durable responses. However, IL-2 has not become a mainstay of treatment because of the expense and toxicity associated with this therapy. This review article discusses a phase II trial that investigates predictive biomarkers that might help clinicians identify the patient population with metastatic RCC that would benefit from IL-2 therapy and therefore limit patients who receive this toxic therapy to those most likely to benefit.


Journal of Oncology Practice | 2017

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer

Jessica M. Clement; Christopher Sweeney

Oligometastatic disease was postulated by Hellman and Weichselbaum in 1995 to be a disease state that may reflect a time point in the malignant process that may be amenable to local therapies to allow for patients to achieve a durable response or possible cure despite having advanced disease. Aggressive metastasis-directed therapy has been used in malignancies such as renal cell carcinoma, non-small-cell lung cancer, and colorectal cancer with some evidence of long-term benefit in selected patients. Recently, it has been proposed that some men with oligometastatic hormone-sensitive prostate cancer may also benefit from metastasis-directed therapy. As with most malignancies, optimal therapy for prostate cancer relies on multimodal therapy, best highlighted by the survival benefit seen in high-volume metastatic prostate cancer with the addition of docetaxel to androgen-deprivation therapy. This is becoming increasingly evident for oligometastatic prostate cancer, with emerging data sets suggesting a possible benefit of local ablative therapies for metastatic lesions combined with androgen-deprivation therapy. However, the bulk of the data is retrospective and thus subject to bias. Ongoing clinical trials are evaluating combination therapy to help elucidate the role of each therapy separately and together to determine optimal interventions for this population. This clinical review discusses the retrospective data evaluating local therapies such as radiation and surgery in men with lymph node-positive disease, as well as limited bone metastases, and outlines ongoing, prospective clinical trials designed to further investigate the role of multimodality therapy in the outcomes of men with oligometastatic hormone-sensitive prostate cancer.


Journal of Oncology Pharmacy Practice | 2016

Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer:

Jay M Patel; Lisa M Holle; Jessica M. Clement; Thomas Bunz; Christopher Niemann; Kevin W Chamberlin

Background With the introduction of oral chemotherapy, the paradigm for cancer treatment is shifting. Use of oral chemotherapy agents offers a non-invasive option for patients with metastatic castrate-resistant prostate cancer. However, these medications are not without challenges including strict adherence for optimal effects, novel toxicity profiles, frequent lab parameter monitoring, high cost, and proper handling and disposal methods. Pharmacists are positioned to play a key role in providing patients with the education required to assure an optimal treatment course is carried out. Methods Two cohorts of patients receiving abiraterone, bicalutamide, or enzalutamide for metastatic castrate-resistant prostate cancer seen in our outpatient cancer center 21 months before and 24 months after the implementation of a pharmacist-led oral chemotherapy-monitoring program in December of 2012 were retrospectively compared. Patients were evaluated for number of interventions, adherence to lab parameter monitoring, and overall time on each therapy. Results Of the 64 patients identified, 31 patients fulfilled inclusion criteria. A significant increase in the average number of interventions per patient (6.9 vs. 2.6; P = 0.004) and adherence to lab parameter monitoring (10 vs. 3; P = 0.04) in the post-program implementation cohort was found. However, no significant difference in overall time on therapy (10.3 vs. 8.1; P = 0.341) between the two groups was observed. Conclusion These results suggest a potential opportunity exists to maximize oral chemotherapy treatment outcomes with the addition of a formalized monitoring program directed by an oncology pharmacist.


Cancer | 2013

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group

Matthew D. Galsky; Ryan Hendricks; Robert S. Svatek; Rick Bangs; Jean H. Hoffman-Censits; Jessica M. Clement; Robert Dreicer; Elizabeth A. Guancial; Noah M. Hahn; Seth P. Lerner; Peter H. O'Donnell; Diane Zipursky Quale; Arlene O. Siefker-Radtke; William U. Shipley; Guru Sonpavde; Daniel Vaena; Jacob Vinson; Jonathan E. Rosenberg

There have been no improvements in the treatment of metastatic urothelial cancer in the past several decades. A census of contemporary clinical research in this disease was performed to identify potential barriers and opportunities.


Journal of Oncology Pharmacy Practice | 2016

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin

Arushi Khurana; Demytra Mitsis; Gurukripa N Kowlgi; Lisa M Holle; Jessica M. Clement

Oxaliplatin, a third-generation, platinum-based agent is widely used, most commonly in the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, which is the first-line therapy in metastatic colorectal adenocarcinoma and adjuvant chemotherapy in stage III colorectal cancer. Platinum-based products are well known for causing hypersensitivity reactions. Fever associated with oxaliplatin-hypersensitivity reactions typically follows a specific pattern. It usually starts during the oxaliplatin infusion or immediately after (within hours instead of days) and happens after several administrations (mean 2–25) with unpredictable clinical presentations. We report a case of oxaliplatin-induced hypersensitivity reaction manifesting as fever but with unusual presentation than the aforementioned features.


Jbjs reviews | 2017

Team Approach: The Treatment of Metastatic Tumors of the Femoral Diaphysis

Michael B. O’Sullivan; Debasmita Saha; Jessica M. Clement; Robert J. Dowsett; Rafael Pacheco; Tessa Balach

The differential diagnosis of an aggressive bone lesion includes metastatic disease, multiple myeloma, lymphoma, and primary sarcoma of bone. Evaluation includes radiographs of the entire bone; laboratory tests; computed tomography (CT) scanning of the chest, abdomen, and pelvis; bone scintigraphy; and biopsy.Except in rare circumstances, the treatment of skeletal metastasis is palliative and the goals of care center around pain relief and the maintenance of function.Nonoperative interventions include chemotherapy, bone-modulating agents such as bisphosphonates and denosumab, radiation therapy, and ablation with cementoplasty.When prophylactic operative stabilization is indicated to prevent pathological fracture, a cephalomedullary nail is preferred for femoral diaphyseal lesions. Postoperative external-beam radiation is indicated for local disease control.High-quality treatment of these patients relies on the close coordination of multiple different specialists.


OncoImmunology | 2015

Smoking-induced immune deviation contributes to progression of bladder and other cancers.

Jessica M. Clement; Fei Duan; Pramod K. Srivastava

We propose here that cigarette smoke (CS), in addition to its established genotoxic effects, elicits chronic albeit sub-clinical immune suppression, which is a major contributor to cancer progression. This hypothesis, presented here primarily in the context of bladder cancers (BCs), is applicable to other cancers, including those without a confirmed link to smoking.


Journal of Oncology Pharmacy Practice | 2018

Potential role of rituximab in metastatic castrate-resistant prostate cancer

Poorva Bindal; Sharif Aa Jalil; Lisa M Holle; Jessica M. Clement

Nearly all men with prostate cancer who are treated with androgen deprivation therapy develop disease progression. There is considerable evidence to suggest that CXCL 13 released by tumor cells leads to B-cell infiltration into the prostate cells. This B-cell infiltration has been postulated to play a role in development of disease progression following androgen-deprivation therapies. We present a case of a patient who achieved remission of metastatic castrate-resistant prostate cancer after receiving rituximab and bendamustine for the treatment of follicular lymphoma. The findings in this report suggest that further investigation is warranted for utilizing B-cell targeted therapy in delaying progression of castrate-resistant prostate cancer.


Urologic Oncology-seminars and Original Investigations | 2017

SATB1 and bladder cancer: Is there a functional link?

Dharamainder Choudhary; Jessica M. Clement; Shilpa Choudhary; Olga Voznesensky; Carol C. Pilbeam; Benjamin L. Woolbright; John A. Taylor

PURPOSE SATB1, a global genome organizer, has been shown to play a role in the development and progression of some solid tumors, but its role in bladder cancer is undetermined. Moreover, there is conflicting data about the role of SATB1 in other tumors. This study was initiated to assess a potential role for SATB1 with the hypothesis that SATB1 acts as a tumor promoter in bladder cancer. MATERIALS AND METHODS We evaluated SATB1 expression in bladder cancer cell lines (HTB-5, HTB-9) and compared them to a benign urothelial cell line (UROtsa). Short-hairpin RNA was used to silence SATB1 in multiple cell lines, and cell death and cell proliferation were assessed using multiple assays. RESULTS SATB1 expression was increased significantly in all cancer cell lines compared to benign urothelial cells. SATB1 expression was knocked down by short-hairpin RNA and functional outcomes, including cell number, cell-cycle arrest, cell viability, and apoptosis after cisplatin treatment, were measured. Surprisingly, knockdown of SATB1 in 2 high-grade cancer cell lines showed opposing functional roles. Compared to the non-silencing control, HTB-5 cells, showed decreased cellular proliferation and increased sensitivity to cisplatin, whereas HTB-9 cells, showed increased cell numbers and increased resistance to cisplatin. CONCLUSION We conclude that our results in bladder cancer are consistent with the conflicting data reported in other cancers, and that SATB1 might have different roles in cancer dependent on genetic background and stage of the cancer.

Collaboration


Dive into the Jessica M. Clement's collaboration.

Top Co-Authors

Avatar

David F. McDermott

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Lisa M Holle

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William Oh

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anthony A. Amato

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Faripour Forouhar

University of Connecticut Health Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge